Does LUSPATERCEPT Cause Extramedullary haemopoiesis? 10 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 10 reports of Extramedullary haemopoiesis have been filed in association with LUSPATERCEPT (Reblozyl). This represents 3.8% of all adverse event reports for LUSPATERCEPT.
10
Reports of Extramedullary haemopoiesis with LUSPATERCEPT
3.8%
of all LUSPATERCEPT reports
0
Deaths
2
Hospitalizations
How Dangerous Is Extramedullary haemopoiesis From LUSPATERCEPT?
Of the 10 reports, 2 (20.0%) required hospitalization.
Is Extramedullary haemopoiesis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LUSPATERCEPT. However, 10 reports have been filed with the FAERS database.
What Other Side Effects Does LUSPATERCEPT Cause?
Death (16)
Off label use (12)
Fatigue (11)
Anaemia (10)
Pneumonia (10)
Drug ineffective (9)
Haemoglobin decreased (9)
Thrombocytopenia (9)
Cerebrovascular accident (8)
Covid-19 (8)
What Other Drugs Cause Extramedullary haemopoiesis?
LUSPATERCEPT-AAMT (20)
RUXOLITINIB (18)
FILGRASTIM (10)
CYCLOPHOSPHAMIDE (9)
VINCRISTINE (9)
DOXORUBICIN (8)
DEXAMETHASONE (7)
RITUXIMAB (7)
BUSULFAN (6)
FLUDARABINE (6)
Which LUSPATERCEPT Alternatives Have Lower Extramedullary haemopoiesis Risk?
LUSPATERCEPT vs LUSPATERCEPT-AAMT
LUSPATERCEPT vs LUTEIN
LUSPATERCEPT vs LUTETIUM LU-177
LUSPATERCEPT vs LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
LUSPATERCEPT vs LUTETIUM OXODOTREOTIDE LU-177